Authors
Latest:
COUNTERPOINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate CancerAbiraterone has become the first-choice treatment for men with metastatic prostate cancer.
Latest:
Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast CancerHere, we discuss how to improve adherence to endocrine therapy in women with HR-positive breast cancer, as well as the side effects and the reasons for discontinuation.
Latest:
Immunizing Cancer Patients: Which Patients? Which Vaccines? When to Give?This article provides guidance to oncology clinicians on vaccine recommendations and safety of use in their patients.
Latest:
Robert Chapkin on Relationships Between the Gut Microbiome, Diet, and Colorectal CancerIn this Q&A, we discuss the research into the relationships between gut microbiota, diet, and colorectal cancer.
Latest:
Erdafitinib in the Treatment of Metastatic Urothelial CarcinomaFrancisco Castro-Alonso, MD, and colleagues describe the effects of the use of erdafitinib in a patient with metastatic urothelial bladder cancer.
Latest:
Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk FactorsA 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.
Latest:
Initiation of ADT in a Man With Locally Advanced Prostate Cancer and Multiple Cardiovascular Risk FactorsA 65-year-old man presented with locally advanced, high-risk prostate cancer. His medical history was remarkable for type 2 diabetes mellitus, and he was an active smoker with a 27 pack-year history.
Latest:
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR-positive breast cancer.
Latest:
CDK4/6 Inhibitors: Game Changers in the Management of Hormone Receptor–Positive Advanced Breast Cancer?Here, we review the current use of and potential next directions for CDK4/6 inhibitors in the treatment of patients with HR-positive breast cancer.
Latest:
Treatment Practices in Metastatic MelanomaAllison Betof Warner, MD, PhD, and the Oncology Brothers share clinical insights on treatment decisions for patients with metastatic melanoma.
Latest:
Synthetic Lethality of PARP Inhibitors in Prostate CancerIn this podcast, Dr. Emmanuel Antonarakis discusses his novel clinical trial evaluating PARP inhibitors in high-risk and biochemically recurrent prostate cancer.
Latest:
The Stand Up 2 Cancer Colorectal Dream TeamDuring AACR 2018, Dr. Diaz discusses the progress of his laboratory’s colorectal cancer research as part of the Stand Up 2 Cancer Colorectal Dream Team.
Latest:
ONS Role in New Guideline for irAE ManagementIn this podcast, Kelly Brassil, PhD, RN, discusses irAEs and ONS’s role in developing an ASCO/NCCN guideline for their management.
Latest:
Misinformation Rampant Among Cancer PatientsCancer patients get inundated with advice, but how much of it can be trusted? Patient advocate Suzie Siegel weighs in.
Latest:
Halt in Production of Codman Pump Leaves QuestionsMSKCC’s Dr. Nancy Kemeny discusses the impact of a company's decision to halt manufacture of a pump used to treat liver mets from colon and rectal cancers.
Latest:
TNM Tumor Staging Revisited: A Look at Updated AJCC GuidelinesUpdates to the 8th edition of AJCC's staging manual include incorporation of more nonanatomic features. Oncology Clinical Specialist Chelsea Backler discussed key changes during the 2018 ONS Congress.
Latest:
How to Build a System-Wide Ambulatory Navigation ProgramAlisa Domb highlighted training and workflow optimization for an ambulatory-setting navigation program covering 10 hem/onc clinics and 2 cancer centers, during the 2018 ONS Congress.
Latest:
ASCO Preview: Lymphoma Presentation HighlightsJoshua Brody discusses ECHELON-1 and its subanalyses, the results of which are anticipated to change the management of Hodgkin lymphoma.
Latest:
ASCO 2018 Highlights: GI and Hepatic Toxicities of Immune Checkpoint Inhibitor TherapyIn this podcast, ASCO Educational Book contributor Dr. Shilpa Grover, from Brigham and Women’s Hospital, describes GI and hepatic AEs encountered in patients on ICI therapy.
Latest:
POINT: Does Chemoimmunotherapy Still Have a Role in CLL?Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.
Latest:
POINT: Does Chemoimmunotherapy Still Have a Role in CLL?Until the superiority of novel agents is proven for all prognostically relevant subgroups of patients with CLL, we believe chemoimmunotherapy continues to have a role.
Latest:
Jennifer A. Woyach, MD, Discusses Use of Ibrutinib in CLL at 2021 ASHJennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.
Latest:
Management of Gastrointestinal Toxicities From Ixazomib: Tips to Curb Nausea, Vomiting, Diarrhea, and ConstipationAn oncology pharmacist discusses how to manage GI toxicities in multiple myeloma patients.
Latest:
How to Decide Which DLBCL Patients Should Receive CNS ProphylaxisHere we review current prognostic models, risk factors, and prophylaxis methods to provide a practical approach to preventing CNS relapse in patients with DLBCL.
Latest:
Kelly Valla, PharmD, BCOP, on Secondary Malignancies With Tazemetostat for Follicular LymphomaAn oncology pharmacist talks secondary malignancies noted with tazemetostat in the treatment of follicular lymphoma.
Latest:
Understanding the Benefits of Acupuncture Treatment for Cancer Pain ManagementThis article reviews how acupuncture is thought to work, data on acupuncture for managing pain caused by cancer or by cancer treatment, how acupuncture is practiced in the US medical system, discussion of safety issues, and practical tips on how to integrate acupuncture into cancer care.
Latest:
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast CancerA 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
Latest:
A 35-Year-Old Woman With a Change in HER2 Expression Following Neoadjuvant Chemotherapy for Invasive Breast CancerA 35-year-old woman noticed a mass in her right breast and underwent a diagnostic workup, including a mammogram that revealed a 2.4-cm mass and ultrasound that showed two adjacent masses, as well as enlarged axillary lymph nodes.
Latest:
Highlights of USPSTF Updates to Prostate Cancer Screening GuidelinesUSPSTF Vice-Chair Alex Krist and prostate cancer specialist David Penson shared perspectives on USPSTF’s updated prostate cancer screening recommendation.
Latest:
How LGL T-Cell Leukemia at 19 Gave Me Empathy for My Patients-and My ColleaguesLate last year, ONCOLOGY hosted a writing contest on Cancer Network, in which we asked our readers to share their personal experiences with delivering bad news. Dr. Trevor Bayliss submitted a piece about his experience as a young patient, and how that influenced his decision to become an oncologist.
